Skip to content

Comparative Clinical Study Of Dexmedetomidine Vs Clonidine For Hemodynamic Stability

Randomised Prospective Comparative Clinical Study Of Dexmedetomidine Vs Clonidine For Hemodynamic Stability During Laproscopic Surgeries In General Anaesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053563
Enrollment
120
Registered
2023-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Dexmedetomidine: Dexmedetomidine is Alfa2 receptor agonist Dose 2microgram/kg iv infusion over 10 min Intervention2: clonidine: Clonidine is Alfa2 receptor agonist DOSE 1 microgram/kg

Sponsors

ARTI YADAV
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA Physical status I and II

Exclusion criteria

Exclusion criteria: 1. Patient refusal 2. History of laryngeal or tracheal surgery or pathology. 3. History of Bronchial asthma, 4. History of smoking, alcohol addiction or drug abuse. 5. Patients with coexisting systemic illness, morbid obese patient, neurological or psychological disease, hepatic or renal dysfunction, endocrinal or metabolic disorder. 6. Patients with hypertensive heart disease or on antihypertensives, beta blockers or calcium channel blockers. 7. Patient with known hypersensitivity or drug allergies. 8. Age less than 18 or more than 60. 9. Basal heart rate less than 60 and patient with heart block or with conduction defect. 10. Active upper respiratory tract infections. 11. Patients with difficult airway MP grade III and IV. 12. Pregnant or lactating female

Design outcomes

Primary

MeasureTime frame
1. To evaluate and compare the intraoperative hemodynamic parameter with intravenous dexmedetomidine and intravenous clonidine as premedication during laproscopic surgeries under general anaesthesia.Timepoint: vital monitoring was done at baseline ,1 min before premedication ,1 min after premedication,1 min before induction,1 min after induction,1 min before intubation ,1 min after intubation,2 min,4 min,6 min,8 min ,10 min ,1 min after CO2 insufflation,after 15 min,at 5 min time interval up to 90 min .

Secondary

MeasureTime frame
To evaluate Side effects of intravenous dexmedetomidine and clonidine.Timepoint: 1 min after giving drugs,2min,4min,6min,8min 10 min at 5 min time interval up to 90 min .

Countries

India

Contacts

Public ContactARTI YADAV

Swami vivekanand subharti university

Drsalonysumitagarwal@gmail.com9557038599

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026